Oncoclínicas do Brasil Serviços Médicos (ONCO3) Q4 2024 earnings summary

Executive summary

• 2024 was a year of transition, with a focus on building a healthier foundation, organic net debt reduction of R$112.3 million in 4Q24, and improved leverage to 2.7x Net Debt/Annualized Adjusted EBITDA.

• Gross revenue reached R$6.8 billion in 2024, up 13.5% year-over-year; net revenue was R$6.2 billion, also up 13.5%.

• A R$1.5 billion capital increase improved liquidity and capital structure, supporting future growth cycles.

• Operational and commercial strategies prioritized cash generation, sustainability, and a shift from cash burn to positive cash flow.

• Significant non-cash, non-recurring impairment of R$796.1 million was recognized due to revised expectations for acquired assets.

Financial highlights

• Gross revenue in Q4 was R$1,716.8 million, up 9.2% year-over-year; annual gross revenue was R$6.8 billion, up 13.5%.

• Procedures increased 6.2% in Q4 year-over-year and 9.0% for the full year; average ticket rose 4.4% in 2024.

• Adjusted EBITDA for Q4 was R$272.1 million (margin 17.4%); full-year Adjusted EBITDA was R$1,152.7 million (margin 18.5%).

• Net profit excluding PILP/LTIP and impairment was R$42.6 million in Q4 and R$106.3 million for 2024.

• Free cash flow was neutral/positive for the second consecutive quarter; net debt reduced by R$112.3 million in Q4.

Outlook and guidance

• Expectation of margin recovery and top-line growth reacceleration in 2025 as restructuring costs subside and new commercial agreements ramp up.

• Commercial strategy prioritizes cash flow generation, cost discipline, and working capital improvements.

• No specific numerical guidance for 2025, but management is optimistic about operational leverage and margin improvement.